# US 2018/0021480 A1 · Composition comprising hyaluronic acid and mepivacaine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021480 A1
- Document ID: US20180021480A1
- Status: Published application
- Kind: A1
- Application number: 15/705,809
- Filed: 2017-09-15
- Published: 2018-01-25
- Earliest claimed: 2013-07-30
- Assignees: Teoxane
- Applicants: Teoxane
- Inventors: FRANCOIS BOURDON; Stephane Meunler
- Web page: https://patentgrep.com/patent/US20180021480A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61K 8/24: Phosphorous; Compounds thereof
- A61K 8/4926: {having six membered rings}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/728: Hyaluronic acid
- A61K 47/02: Inorganic compounds
- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 27/20: Polysaccharides
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 23/00: Anaesthetics
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/524: Preservatives
- A61K 2800/75: Anti-irritant
- A61K 2800/91: Injection
- A61L 2300/204: with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2400/06: Flowable or injectable implant compositions
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

## Claims

### Claim 1

A sterile, injectable composition for intraepidermal, intradermal, and/or subcutaneous administration comprising:
hyaluronic acid or a salt thereof at a concentration ranging from 0.1 to 5 wt % of an overall weight of the sterile injectable composition,
mepivacaine or a salt thereof as a first anesthetic agent at a concentration ranging from 0.05 to 3 wt % of the overall weight of the sterile, injectable composition, and
an additional compound comprising at least one of an antioxidant(s), amino acid(s), vitamin(s), mineral(s), nucleic acid(s), co-enzyme(s), adrenaline, noradrenaline, or mixtures thereof.

### Claim 2 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound is an antioxidant.

### Claim 3 (depends on 2)

The sterile, injectable composition of claim 2 wherein the salt of mepivacaine is chlorhydrate mepivacaine.

### Claim 4 (depends on 2)

The sterile, injectable composition of claim 2, further comprising a balanced salt solution.

### Claim 5 (depends on 2)

The sterile, injectable composition of claim 2, further comprising phosphate saline buffer.

### Claim 6 (depends on 2)

The sterile, injectable composition of claim 2, wherein the antioxidant comprises glutathione, ellagic acid, spermine, resveratrol, retinol, L-carnitine, polyol(s), polyphenol(s), flavonol(s), theaflavin(s), catechin(s), caffeine, ubiquinol, ubiquinone, or mixture thereof.

### Claim 7 (depends on 6)

The sterile, injectable composition of claim 6, wherein the hyaluronic acid or the salt thereof has an average molecular weight ranging from 50,000 to 10,000,000 Daltons.

### Claim 8 (depends on 7)

The sterile, injectable composition of claim 7, wherein the hyaluronic acid or the salt thereof is selected from the group consisting of crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, and a mixture thereof

### Claim 9 (depends on 8)

The sterile, injectable composition of claim 8, wherein the hyaluronic acid or the salt thereof comprises crosslinked and non-crosslinked hyaluronic acids at a ratio ranging from 1:1 to 1:0.02 of crosslinked to non-crosslinked hyaluronic acid in the single, sterile injectable composition.

### Claim 10 (depends on 9)

The sterile, injectable composition of claim 9, further comprising a balanced salt solution.

### Claim 11 (depends on 10)

The sterile, injectable composition of claim 10, wherein the balanced salt solution is a phosphate saline buffer.

### Claim 12 (depends on 11)

The sterile, injectable composition of claim 11, wherein the salt of mepivacaine is chlorhydrate mepivacaine.

### Claim 13 (depends on 12)

The sterile, injectable composition of claim 12, further comprising a second anesthetic agent.

### Claim 14 (depends on 2)

The sterile injectable composition of claim 2, wherein the antioxidant comprises a polyol.

### Claim 15 (depends on 4)

The sterile, injectable composition of claim 4, wherein the hyaluronic acid or the salt thereof has an average molecular weight ranging from 50,000 to 10,000,000 Daltons.

### Claim 16 (depends on 5)

The sterile, injectable composition of claim 5, wherein the hyaluronic acid or the salt thereof is selected from the group consisting of crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, and a mixture thereof.

### Claim 17 (depends on 6)

The sterile, injectable composition of claim 6, wherein the hyaluronic acid or the salt thereof comprises crosslinked and non-crosslinked hyaluronic acids at a ratio ranging from 1:1 to 1:0.02 of crosslinked to non-crosslinked hyaluronic acid in the single, sterile injectable composition.

### Claim 18 (depends on 7)

The sterile, injectable composition of claim 7, further comprising a balanced salt solution.

### Claim 19 (depends on 8)

The sterile, injectable composition of claim 8, wherein the balanced salt solution is a phosphate saline buffer.

### Claim 20 (depends on 9)

The sterile, injectable composition of claim 9 wherein the salt of mepivacaine is chlorhydrate mepivacaine.

### Claim 21 (depends on 10)

The sterile, injectable composition of claim 10, further comprising a second anesthetic agent.

### Claim 22 (depends on 13)

The sterile, injectable composition of claim 13, wherein the second anesthetic agent comprises at least one of ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethysoquine, dimethocaine, diperodone, dycyclonine, ecgonidine, ecgonine, ethyl chloride, etidocaine, beta-eucaine, euprocine fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoxadrol, lidocaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octacaine, orthocaine, oxethazaine, parethoxycaine, phenacaine, phenol, piperocaine, piridocaine, polidocanol, pramoxine, prilocaine, procaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, ropivacaine, salicyl alcohol, tetracaine, tolycane, trimecaine, zolamine, or a salt thereof, or mixtures thereof.

### Claim 23 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound comprises an antioxidant and an amino acid, the amino acid selected from the group consisting of arginine, isoleucine, leucine, lysine, glycine, valine, threonine, proline, methionine, histidine, phenylalanine, tryptophan, and mixturemixtures thereof.

### Claim 24 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound comprises an antioxidant and a vitamin, the vitamin selected from the group consisting of vitamin E, vitamin A, vitamin C, vitamin B, or mixtures thereof.

### Claim 25 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound comprises an antioxidant and a mineral, the mineral selected from the group consisting of zinc salts, magnesium salts, calcium salts, potassium salts, manganese salts, sodium salts, and mixtures thereof

### Claim 26 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound comprises an antioxidant and a nucleic acid, the nucleic acid selected from the group consisting of adenosine, cytidine, guanosine, thymidine and mixtures thereof.

### Claim 27 (depends on 1)

The sterile, injectable composition of claim 1, wherein the additional compound comprises an antioxidant and a co-enzyme, the co-enzyme selected from the group consisting of coenzyme Q10, CoA, NAD, NADP, or mixtures thereof

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The sterile, injectable composition of claim 1, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and mixtures thereof.

### Claim 30 (depends on 1)

The sterile, injectable composition of claim 1, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE).

### Claim 31 (depends on 2)

The sterile, injectable composition of claim 2, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and mixtures thereof.

### Claim 32 (depends on 2)

The sterile, injectable composition of claim 2, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE).

### Claim 33 (depends on 14)

The sterile, injectable composition of claim 14 wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with at least one crosslinker selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, an endogenous polyamine, and mixtures thereof.

### Claim 34 (depends on 14)

The sterile, injectable composition of claim 14, wherein the hyaluronic acid or a salt thereof comprises hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE).
